3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
16
Thoracic
6
Gastrointestinal
6
Breast
6
Dermatologic
4
Genitourinary
3
Head & Neck
2
CNS
2
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
8
Lymphoma, Non-Hodgkin
4
Leukemia, Myeloid, Acute
3
Hematologic Neoplasms
3
Neoplasm Metastasis
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Hodgkin Disease
2
Colorectal Neoplasms
2
Stomach Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Neoplasms
1
Myelodysplastic Syndromes
1
Melanoma
1
Lymphoma, Follicular
1
Lymphoma
1
Liver Neoplasms
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia
1
Glioblastoma
1
Esophageal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Amyloidosis
1
Interventions
Cyclophosphamide
6
fludarabine
4
Magnetic Resonance Spectroscopy
3
Flow Cytometry
3
trametinib
2
pembrolizumab
2
liposomal doxorubicin
2
dabrafenib
2
aldesleukin
2
Specimen Handling
2
Methylprednisolone
2
Immunologic Techniques
2
Gemcitabine
2
Dexamethasone
2
Biopsy
2
Azacitidine
2
Alemtuzumab
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
sargramostim
1
saracatinib
1
sapanisertib
1
ruxolitinib
1
rucaparib
1
resiquimod
1
relatlimab
1
poly ICLC
1
pertuzumab
1
palbociclib
1
osimertinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Interleukin-2
×
Plasma cell
×
Clear all
NCT07410494
2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2
Recruiting
85 enrolled